- Home
- ROIV vs CNC Comparison
ROIV vs CNC Comparison
Compare ROIV & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | CNC |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 34.0B |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CNC |
|---|---|---|
| Price | $36.89 | $68.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 21 |
| Target Price | $50.00 | ★ $74.50 |
| AVG Volume (30 Days) | ★ 6.2M | 3.9M |
| Earning Date | 11-09-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.15 |
| Revenue | $8,260,000.00 | ★ $194,777,000,000.00 |
| Revenue This Year | $593.33 | $12.83 |
| Revenue Next Year | $648.48 | N/A |
| P/E Ratio | ★ N/A | $13.27 |
| Revenue Growth | N/A | ★ 19.44 |
| 52 Week Low | $19.30 | $31.63 |
| 52 Week High | $42.50 | $72.50 |
Technical Indicators
Market Signals| Indicator | ROIV | CNC |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 51.54 |
| Support Level | $33.11 | $63.36 |
| Resistance Level | $37.89 | $68.67 |
| Average True Range (ATR) | 1.25 | 2.70 |
| MACD | 0.32 | -0.21 |
| Stochastic Oscillator | 70.31 | 33.09 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CNC Centene Corporation
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.